Researchers at Houston Methodist Research Institute were awarded a nearly $4 million grant from the National Institute of Allergy and Infectious Diseases to…

Woburn, MA-based Aphios said it landed a subcontract for the nanoformulation of a new superhydrophobic anticancer drug called Brefeldin A.

Amgen said the FDA has approved its Repatha (evolocumab) Pushtronex system, the first hands-free, once-monthly delivery option for a PCSK9 inhibitor.

The New Jersey Institute of Technology received a $1 million grant from the W. M. Keck Foundation it will use to study new materials for nanotechnology.

Researchers at Memorial Sloan Kettering have uncovered a new way to target drugs specifically to cancer sites in the body, including metastatic tumors.

Onxeo, a developer of orphan oncology drugs, is partnering with the Royal College of Surgeons in Ireland (RCSI) as part of a discovery-stage program focused on…

AntriaBio, a biopharma focused on developing novel extended-release therapies, has raised $12 million in a private placement deal.

The FDA issued a complete response letter to Lipocine for its testosterone replacement treatment, citing issues with the drug’s dosing algorithm for the label.

Privately held JDP Therapeutics said it secured $17 million in Series A funding it plans to use to develop the company’s injectable drug used to treat acute…